

Robert Zeiser

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/748896/publications.pdf>

Version: 2024-02-01

187
papers

12,699
citations

23544

58
h-index

29127

104
g-index

192
all docs

192
docs citations

192
times ranked

14732
citing authors

#	ARTICLE	IF	CITATIONS
1	Acute Graft-versus-Host Disease – Biologic Process, Prevention, and Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 2167-2179.	13.9	822
2	Pathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets. <i>New England Journal of Medicine</i> , 2017, 377, 2565-2579.	13.9	469
3	Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. <i>Blood</i> , 2006, 108, 390-399.	0.6	467
4	Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. <i>Leukemia</i> , 2015, 29, 2062-2068.	3.3	455
5	Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2020, 382, 1800-1810.	13.9	455
6	Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. <i>Nature Medicine</i> , 2010, 16, 1434-1438.	15.2	376
7	Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. <i>Blood</i> , 2008, 111, 453-462.	0.6	359
8	Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease. <i>Blood</i> , 2014, 123, 3832-3842.	0.6	336
9	Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. <i>Lancet Haematology</i> , 2020, 7, e157-e167.	2.2	319
10	Continuous T Cell Receptor Signals Maintain a Functional Regulatory T Cell Pool. <i>Immunity</i> , 2014, 41, 722-736.	6.6	262
11	Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. <i>Nature Medicine</i> , 2019, 25, 603-611.	15.2	253
12	Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. <i>Nature</i> , 2019, 572, 254-259.	13.7	246
13	Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage. <i>Nature Medicine</i> , 2014, 20, 648-654.	15.2	241
14	Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. <i>Nature Medicine</i> , 2018, 24, 282-291.	15.2	216
15	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2021, 385, 228-238.	13.9	209
16	The Nlrp3 inflammasome regulates acute graft-versus-host disease. <i>Journal of Experimental Medicine</i> , 2013, 210, 1899-1910.	4.2	201
17	Immune modulatory effects of oncogenic KRAS in cancer. <i>Nature Communications</i> , 2020, 11, 5439.	5.8	188
18	Lack of the purinergic receptor P2X7 results in resistance to contact hypersensitivity. <i>Journal of Experimental Medicine</i> , 2010, 207, 2609-2619.	4.2	183

#	ARTICLE	IF	CITATIONS
19	Oncogenic JAK2 ^{V617F} causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
20	MHC Class II Antigen Presentation by the Intestinal Epithelium Initiates Graft-versus-Host Disease and Is Influenced by the Microbiota. <i>Immunity</i> , 2019, 51, 885-898.e7.	6.6	164
21	Immune modulatory effects of statins. <i>Immunology</i> , 2018, 154, 69-75.	2.0	161
22	NLRP3 Inflammasome Activation in Cancer: A Double-Edged Sword. <i>Frontiers in Immunology</i> , 2020, 11, 1444.	2.2	148
23	HIF-1 α and HIF-2 α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. <i>Nature Communications</i> , 2020, 11, 4111.	5.8	141
24	The IL-33/ST2 axis augments effector T-cell responses during acute GVHD. <i>Blood</i> , 2015, 125, 3183-3192.	0.6	133
25	P2X ₇ Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 44, 423-429.	1.4	130
26	Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT. <i>Nature Communications</i> , 2019, 10, 1065.	5.8	120
27	Purinergic Receptor Inhibition Prevents the Development of Smoke-Induced Lung Injury and Emphysema. <i>Journal of Immunology</i> , 2010, 185, 688-697.	0.4	119
28	GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. <i>Blood</i> , 2015, 126, 1621-1628.	0.6	104
29	MicroRNA-155 ^{-/-} deficient dendritic cells cause less severe GVHD through reduced migration and defective inflammasome activation. <i>Blood</i> , 2015, 126, 103-112.	0.6	104
30	Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. <i>British Journal of Haematology</i> , 2016, 175, 191-207.	1.2	103
31	BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. <i>Blood</i> , 2016, 127, 2847-2855.	0.6	100
32	MicroRNA-100 Suppresses Chronic Vascular Inflammation by Stimulation of Endothelial Autophagy. <i>Circulation Research</i> , 2018, 122, 417-432.	2.0	100
33	Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2019, 133, 1290-1297.	0.6	100
34	MiR-146a regulates the TRAF6/TNF-axis in donor T cells during GVHD. <i>Blood</i> , 2014, 124, 2586-2595.	0.6	95
35	Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity. <i>Blood</i> , 2007, 110, 4588-4598.	0.6	94
36	Neutrophils provide cellular communication between ileum and mesenteric lymph nodes at graft-versus-host disease onset. <i>Blood</i> , 2018, 131, 1858-1869.	0.6	94

#	ARTICLE	IF	CITATIONS
37	Oncogenic KrasG12D causes myeloproliferation via NLRP3 inflammasome activation. <i>Nature Communications</i> , 2020, 11, 1659.	5.8	92
38	Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. <i>Blood</i> , 2016, 128, 427-439.	0.6	91
39	Splicing factor YBX1 mediates persistence of JAK2-mutated neoplasms. <i>Nature</i> , 2020, 588, 157-163.	13.7	90
40	Danger signals activating innate immunity in graft-versus-host disease. <i>Journal of Molecular Medicine</i> , 2011, 89, 833-845.	1.7	89
41	MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. <i>Leukemia</i> , 2017, 31, 2732-2741.	3.3	88
42	Sorafenib As Maintenance Therapy Post Allogeneic Stem Cell Transplantation for FLT3-ITD Positive AML: Results from the Randomized, Double-Blind, Placebo-Controlled Multicentre Sormain Trial. <i>Blood</i> , 2018, 132, 661-661.	0.6	87
43	MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization. <i>Circulation</i> , 2015, 131, 1575-1589.	1.6	85
44	Metabolic conditioning of CD8+ effector T cells for adoptive cell therapy. <i>Nature Metabolism</i> , 2020, 2, 703-716.	5.1	83
45	Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. <i>International Journal of Cancer</i> , 2006, 119, 2428-2434.	2.3	81
46	Impact of Mammalian Target of Rapamycin Inhibition on Lymphoid Homing and Tolerogenic Function of Nanoparticle-Labeled Dendritic Cells following Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Immunology</i> , 2008, 181, 4770-4779.	0.4	81
47	Deficiency of CD73/ecto-5'-nucleotidase in mice enhances acute graft-versus-host disease. <i>Blood</i> , 2012, 119, 4554-4564.	0.6	81
48	Inflammatory neovascularization during graft-versus-host disease is regulated by α v integrin and miR-100. <i>Blood</i> , 2013, 121, 3307-3318.	0.6	75
49	5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft. <i>Bone Marrow Transplantation</i> , 2015, 50, 690-695.	1.3	73
50	Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. <i>Blood</i> , 2007, 109, 2225-2233.	0.6	72
51	Interleukin-2 receptor downstream events in regulatory T cells: Implications for the choice of immunosuppressive drug therapy. <i>Cell Cycle</i> , 2008, 7, 458-462.	1.3	71
52	Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACHÂ trials. <i>Immunotherapy</i> , 2018, 10, 391-402.	1.0	71
53	Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	70
54	miR-146a Controls Immune Response in the Melanoma Microenvironment. <i>Cancer Research</i> , 2019, 79, 183-195.	0.4	69

#	ARTICLE	IF	CITATIONS
55	Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?. <i>Blood</i> , 2016, 127, 3117-3126.	0.6	68
56	Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	68
57	Noncanonical binding of Lck to CD3 ζ promotes TCR signaling and CAR function. <i>Nature Immunology</i> , 2020, 21, 902-913.	7.0	68
58	Matching for the nonconventional MHC-I MICA gene significantly reduces the incidence of acute and chronic GVHD. <i>Blood</i> , 2016, 128, 1979-1986.	0.6	66
59	Evaluation of immunomodulatory treatment based on conventional and lineage-specific chimerism analysis in patients with myeloid malignancies after myeloablative allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , 2005, 19, 814-821.	3.3	64
60	Advances in understanding the pathogenesis of graft-versus-host disease. <i>British Journal of Haematology</i> , 2019, 187, 563-572.	1.2	64
61	Therapeutic activity of multiple common γ -chain cytokine inhibition in acute and chronic GVHD. <i>Blood</i> , 2015, 125, 570-580.	0.6	63
62	Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin- β 1 expression. <i>Oncotarget</i> , 2017, 8, 42901-42916.	0.8	60
63	Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans. <i>Blood</i> , 2020, 136, 1442-1455.	0.6	60
64	BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2014, 124, 5074-5084.	3.9	56
65	B7-H3 expression in donor T cells and host cells negatively regulates acute graft-versus-host disease lethality. <i>Blood</i> , 2015, 125, 3335-3346.	0.6	55
66	The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior. <i>EBioMedicine</i> , 2017, 20, 79-97.	2.7	55
67	New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions. <i>Frontiers in Immunology</i> , 2020, 11, 578314.	2.2	55
68	Allogeneic transplantation of multiple myeloma patients may allow long-term survival in carefully selected patients with acceptable toxicity and preserved quality of life. <i>Haematologica</i> , 2019, 104, 370-379.	1.7	53
69	B-cell targeting in chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 1399-1405.	0.6	52
70	A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells during Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2015, 195, 5795-5804.	0.4	51
71	Danger-associated extracellular ATP counters MDSC therapeutic efficacy in acute GVHD. <i>Blood</i> , 2019, 134, 1670-1682.	0.6	49
72	β 2-microglobulin triggers NLRP3 inflammasome activation in tumor-associated macrophages to promote multiple myeloma progression. <i>Immunity</i> , 2021, 54, 1772-1787.e9.	6.6	49

#	ARTICLE	IF	CITATIONS
73	MicroRNA-146a regulates immune-related adverse events caused by immune checkpoint inhibitors. <i>JCI Insight</i> , 2020, 5, .	2.3	49
74	Graft-versus-host disease prophylaxis: Pathophysiology-based review on current approaches and future directions. <i>Blood Reviews</i> , 2021, 48, 100792.	2.8	48
75	CXCL12 Mediates Immunosuppression in the Lymphoma Microenvironment after Allogeneic Transplantation of Hematopoietic Cells. <i>Cancer Research</i> , 2010, 70, 10170-10181.	0.4	47
76	The Role of Purine Metabolites as DAMPs in Acute Graft-versus-Host Disease. <i>Frontiers in Immunology</i> , 2016, 7, 439.	2.2	47
77	CXCR4 antagonists suppress small cell lung cancer progression. <i>Oncotarget</i> , 2016, 7, 85185-85195.	0.8	47
78	Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels. <i>Leukemia</i> , 2012, 26, 1617-1629.	3.3	45
79	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. <i>Nature Communications</i> , 2021, 12, 6436.	5.8	45
80	Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. <i>Blood</i> , 2016, 127, 1930-1939.	0.6	44
81	B-Raf Inhibitors Induce Epithelial Differentiation in <i>BRAF</i> -Mutant Colorectal Cancer Cells. <i>Cancer Research</i> , 2015, 75, 216-229.	0.4	43
82	Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). <i>BMC Cancer</i> , 2018, 18, 1132.	1.1	41
83	Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e128-e140.	2.0	40
84	Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD. <i>Frontiers in Immunology</i> , 2018, 9, 3179.	2.2	38
85	Clinicians and patients perspectives on follow-up care and eHealth support after allogeneic hematopoietic stem cell transplantation: A mixed-methods contextual analysis as part of the SMILe study. <i>European Journal of Oncology Nursing</i> , 2020, 45, 101723.	0.9	37
86	Regulation of different inflammatory diseases by impacting the mevalonate pathway. <i>Immunology</i> , 2009, 127, 18-25.	2.0	35
87	Insights into the pathogenesis of <i>GvHD</i> : what mice can teach us about man. <i>Tissue Antigens</i> , 2015, 85, 2-9.	1.0	35
88	Clinical implications of tumor-intrinsic mechanisms regulating PD-L1. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	35
89	Graft-versus-host disease of the CNS is mediated by TNF upregulation in microglia. <i>Journal of Clinical Investigation</i> , 2020, 130, 1315-1329.	3.9	35
90	Refractory acute graft-versus-host disease: a new working definition beyond corticosteroid refractoriness. <i>Blood</i> , 2020, 136, 1903-1906.	0.6	34

#	ARTICLE	IF	CITATIONS
91	SNAIL1 employs β -Catenin/LEF1 complexes to control colorectal cancer cell invasion and proliferation. International Journal of Cancer, 2020, 146, 2229-2242.	2.3	32
92	Ruxolitinib+EC combination treatment for refractory severe chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 909-916.	1.3	32
93	The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. Blood Advances, 2020, 4, 3789-3794.	2.5	31
94	Three US Food and Drug Administration-approved therapies for chronic GVHD. Blood, 2022, 139, 1642-1645.	0.6	30
95	Activation loop phosphorylation regulates β -Raf <i>in vivo</i> and transformation by β -Raf mutants. EMBO Journal, 2016, 35, 143-161.	3.5	29
96	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. The 2020 Treatment of Chronic GVHD Report. Transplantation and Cellular Therapy, 2021, 27, 729-737.	0.6	29
97	Fever supports CD8 ⁺ effector T cell responses by promoting mitochondrial translation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	28
98	The Role of Immune Checkpoint Molecules for Relapse After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 2021, 12, 634435.	2.2	27
99	Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial. Lancet Haematology, 2022, 9, e14-e25.	2.2	27
100	Trametinib (GSK1120212). Recent Results in Cancer Research, 2018, 211, 91-100.	1.8	26
101	Bile acids regulate intestinal antigen presentation and reduce graft-versus-host disease without impairing the graft-versus-leukemia effect. Haematologica, 2021, 106, 2131-2146.	1.7	26
102	Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector T cells. Haematologica, 2013, 98, 31-40.	1.7	26
103	Unlocking the Potential of Purinergic Signaling in Transplantation. American Journal of Transplantation, 2016, 16, 2781-2794.	2.6	25
104	Immunization against poly-N-acetylglucosamine reduces neutrophil activation and GVHD while sparing microbial diversity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 20700-20706.	3.3	25
105	Nonclassical manifestations of acute GVHD. Blood, 2021, 138, 2165-2172.	0.6	25
106	Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients with Steroid-Refractory/Steroid-Dependent Chronic Graft-Vs-Host Disease (cGVHD): Primary Findings from the Phase 3, Randomized REACH3 Study. Blood, 2020, 136, 22-24.	0.6	24
107	Trametinib. Recent Results in Cancer Research, 2014, 201, 241-248.	1.8	23
108	Loss of LSR affects epithelial barrier integrity and tumor xenograft growth of CaCo-2 cells. Oncotarget, 2017, 8, 37009-37022.	0.8	23

#	ARTICLE	IF	CITATIONS
109	The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1662-1667.	1.3	22
110	Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia. <i>Haematologica</i> , 2020, 105, 1285-1293.	1.7	22
111	Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis. <i>Annals of Hematology</i> , 2014, 93, 1439-1440.	0.8	21
112	The Hematopoietic Niche in Myeloproliferative Neoplasms. <i>Mediators of Inflammation</i> , 2015, 2015, 1-11.	1.4	21
113	Extracorporeal Photopheresis for Colitis Induced by Checkpoint-Inhibitor Therapy. <i>New England Journal of Medicine</i> , 2020, 382, 294-296.	13.9	19
114	Late cytomegalovirus polyradiculopathy following haploidentical CD34+-selected hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2004, 33, 243-245.	1.3	18
115	High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis. <i>European Journal of Immunology</i> , 2019, 49, 462-475.	1.6	18
116	Kinase Inhibition as Treatment for Acute and Chronic Graft-Versus-Host Disease. <i>Frontiers in Immunology</i> , 2021, 12, 760199.	2.2	18
117	Host-Derived Interleukin-18 Differentially Impacts Regulatory and Conventional T Cell Expansion During Acute Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1427-1438.	2.0	17
118	Immunotherapy in Myeloproliferative Diseases. <i>Cells</i> , 2020, 9, 1559.	1.8	17
119	Allogeneic haematopoietic cell transplantation for multiple myeloma: Reducing transplant-related mortality while harnessing the graft-versus-myeloma effect. <i>European Journal of Cancer</i> , 2006, 42, 1601-1611.	1.3	16
120	The role of danger signals and ectonucleotidases in acute graft-versus-host disease. <i>Human Immunology</i> , 2016, 77, 1037-1047.	1.2	16
121	Vismodegib. <i>Recent Results in Cancer Research</i> , 2018, 211, 125-139.	1.8	16
122	Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. <i>Annals of Hematology</i> , 2021, 100, 2339-2350.	0.8	16
123	Insights from integrating clinical and preclinical studies advance understanding of graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	16
124	Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer. <i>Cancer Letters</i> , 2022, 538, 215697.	3.2	16
125	Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 426-445.	0.6	16
126	Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth—the SMILE study. <i>Supportive Care in Cancer</i> , 2021, 29, 8045-8057.	1.0	15

#	ARTICLE	IF	CITATIONS
127	An orthotopic mouse model of small cell lung cancer reflects the clinical course in patients. <i>Clinical and Experimental Metastasis</i> , 2016, 33, 651-660.	1.7	14
128	Detection of major histocompatibility complex molecules in processed allogeneic bone blocks for use in alveolar ridge reconstruction. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2018, 126, 16-21.	0.2	14
129	NPM1c alters FLT3-D835Y localization and signaling in acute myeloid leukemia. <i>Blood</i> , 2019, 134, 383-388.	0.6	14
130	Acute Graft-Versus-Host Disease-Challenge for a Broader Application of Allogeneic Hematopoietic Cell Transplantation. <i>Current Stem Cell Research and Therapy</i> , 2006, 1, 203-212.	0.6	13
131	Metadherin exon 11 skipping variant enhances metastatic spread of ovarian cancer. <i>International Journal of Cancer</i> , 2015, 136, 2328-2340.	2.3	13
132	Immunotherapy for Malignant Melanoma Robert. <i>Current Stem Cell Research and Therapy</i> , 2012, 7, 217-228.	0.6	13
133	Graft-versus-host disease reduces regulatory T cell migration into the tumour tissue. <i>Immunology</i> , 2012, 137, 80-88.	2.0	12
134	P2Y2R Signaling Is Involved in the Onset of Glomerulonephritis. <i>Frontiers in Immunology</i> , 2018, 9, 1589.	2.2	12
135	Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1450-1455.	2.0	12
136	Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 2021, 56, 841-852.	1.3	12
137	Coevolving JAK2V617F+relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case. <i>Blood Advances</i> , 2021, 5, 4701-4709.	2.5	12
138	Novel Biomarkers for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Frontiers in Immunology</i> , 2020, 11, 1854.	2.2	11
139	Trigger-dependent differences determine therapeutic outcome in murine primary hemophagocytic lymphohistiocytosis. <i>European Journal of Immunology</i> , 2020, 50, 1770-1782.	1.6	11
140	Gab2 is essential for Bcr-Abl-mediated leukemic transformation and hydronephrosis in a chronic myeloid leukemia mouse model. <i>Leukemia</i> , 2016, 30, 1942-1945.	3.3	10
141	B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model. <i>Oncogene</i> , 2019, 38, 1324-1339.	2.6	10
142	Dendritic Cell Expression of Retinal Aldehyde Dehydrogenase-2 Controls Graft-versus-Host Disease Lethality. <i>Journal of Immunology</i> , 2019, 202, 2795-2805.	0.4	10
143	Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma. <i>Haematologica</i> , 2020, 105, e523.	1.7	10
144	Immunomodulatory Therapies for the Treatment of Graft-versus-host Disease. <i>HemaSphere</i> , 2021, 5, e581.	1.2	10

#	ARTICLE	IF	CITATIONS
145	IRE1 and PERK signaling regulates inflammatory responses in a murine model of contact hypersensitivity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 966-978.	2.7	10
146	Unusual Cases in Multiple Myeloma and a Dramatic Response in Metastatic Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 230-231.	0.8	9
147	Biology-driven developments in the therapy of acute graft-versus-host disease. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 236-241.	0.9	9
148	Cobimetinib (GDC-0973, XL518). <i>Recent Results in Cancer Research</i> , 2018, 211, 177-186.	1.8	9
149	Introduction to a review series on pathophysiology and treatment of acute GVHD. <i>Blood</i> , 2020, 136, 375-376.	0.6	9
150	In Vivo Myeloperoxidase Imaging and Flow Cytometry Analysis of Intestinal Myeloid Cells. <i>Methods in Molecular Biology</i> , 2016, 1422, 161-167.	0.4	8
151	Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 110-120.	1.3	8
152	Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses. <i>Blood</i> , 2021, 137, 1090-1103.	0.6	8
153	Loss of the Fanconi anemia-associated protein NIPA causes bone marrow failure. <i>Journal of Clinical Investigation</i> , 2020, 130, 2827-2844.	3.9	8
154	GVHD, IBD, and primary immunodeficiencies: The gut as a target of immunopathology resulting from impaired immunity. <i>European Journal of Immunology</i> , 2022, 52, 1406-1418.	1.6	8
155	Retinoic acid signaling acts as a rheostat to balance Treg function. , 2022, 19, 820-833.		8
156	Ectonucleotidases in Solid Organ and Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Biomedicine and Biotechnology</i> , 2012, 2012, 1-17.	3.0	7
157	Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia. <i>Cancer Gene Therapy</i> , 2022, 29, 1751-1760.	2.2	7
158	Baricitinib for patients with severe COVID-19â€”time to change the standard of care?. <i>Lancet Respiratory Medicine</i> , 2022, , .	5.2	6
159	Oncogenic <i>Kras</i> G12D Activation in the Nonhematopoietic Bone Marrow Microenvironment Causes Myelodysplastic Syndrome in Mice. <i>Molecular Cancer Research</i> , 2021, 19, 1596-1608.	1.5	5
160	NKT Cells Are Potent Regulators of GVHD Following Adoptive Transfer in Allogeneic BMT.. <i>Blood</i> , 2007, 110, 353-353.	0.6	5
161	Pregnancy Specific Î²-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival. <i>Journal of Cancer</i> , 2016, 7, 2018-2027.	1.2	4
162	Gab2 is Essential for Transformation by FLT3â€”ITD in Acute Myeloid Leukemia. <i>HemaSphere</i> , 2019, 3, e184.	1.2	4

#	ARTICLE	IF	CITATIONS
163	Existence of reprogrammed lymphoma stem cells in a murine ALCL-like model. <i>Leukemia</i> , 2020, 34, 3242-3255.	3.3	4
164	Interfering With Inflammation: Heterogeneous Effects of Interferons in Graft-Versus-Host Disease of the Gastrointestinal Tract and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2021, 12, 705342.	2.2	4
165	Azacytidine Sensitizes AML Cells for Effective Elimination By CD123 CAR T-Cells. <i>Blood</i> , 2019, 134, 3904-3904.	0.6	4
166	Acute Graft-Versus-Host Disease, Infections, Vascular Events and Drug Toxicities Affecting the Central Nervous System. <i>Frontiers in Immunology</i> , 2021, 12, 748019.	2.2	4
167	Therapeutic targeting of endoplasmic reticulum stress in acute graft-&i>versus&/i>-host disease. <i>Haematologica</i> , 2022, 107, 1538-1554.	1.7	3
168	Decitabine (DAC) in Combination with Donor Lymphocyte Infusions (DLIs) Can Induce Remissions of Overt Aml Relapses after Allogeneic Transplantation. <i>Blood</i> , 2016, 128, 2247-2247.	0.6	3
169	Editorial: Non-coding RNAs and Graft versus Host Disease. <i>Frontiers in Immunology</i> , 2018, 9, 2713.	2.2	2
170	A prospective single-center study on CNI-free GVHD prophylaxis with everolimus plus mycophenolate mofetil in allogeneic HCT. <i>Annals of Hematology</i> , 2021, 100, 2095-2103.	0.8	2
171	Impact of mTOR Inhibition on FoxP3+ Regulatory T Cells as Compared to Conventional T Cells after Allogeneic Bone Marrow Transplantation.. <i>Blood</i> , 2006, 108, 448-448.	0.6	2
172	Age-dependent leiomyuscular atrophy in vertebral arteries of individuals under low fat diet. <i>In Vivo</i> , 2000, 14, 631-4.	0.6	2
173	FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 341-350.	0.7	2
174	Epigenetic Regulation to Enhance Graft-versus-Leukemia Activity. <i>Cancer Discovery</i> , 2022, 12, 1410-1412.	7.7	2
175	Response to Letter Regarding Article, "MicroRNA-155 Exerts Cell-Specific Antiangiogenic but Proarteriogenic Effects During Adaptive Neovascularization" <i>Circulation</i> , 2015, 132, e376.	1.6	1
176	Introduction to a review series on strategies to improve GVL effects. <i>Blood</i> , 2018, 131, 1039-1039.	0.6	1
177	TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis. <i>Leukemia</i> , 2019, 33, 2956-2962.	3.3	1
178	Regulatory T Cells: Broadening Applicability. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 159-177.	0.0	1
179	Deciphering the role of Minor histocompatibility antigens for acute graft-versus-host disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 523-524.	0.6	1
180	Selective Expansion of Human Regulatory (CD4+CD25+CD127LowFOXP3+) Cells to High Purity by Inhibiting Expansion of CD4+CD25+CD127HighFOXP3-Conventional T Cells with Rapamycin.. <i>Blood</i> , 2006, 108, 3162-3162.	0.6	1

#	ARTICLE	IF	CITATIONS
181	Therapy response of glucocorticoid-refractory acute GVHD of the lower intestinal tract. Bone Marrow Transplantation, 0, , .	1.3	1
182	Monitoring of Measurable Residual Disease Using Circulating DNA after Allogeneic Hematopoietic Cell Transplantation. Cancers, 2022, 14, 3307.	1.7	1
183	Extramedullary plasmocytoma with local amyloidosis presenting as a lump on the lip. British Journal of Haematology, 2004, 125, 679-679.	1.2	0
184	Immunotherapeutic approaches targeting prostate cancer and its microenvironment. Memo - Magazine of European Medical Oncology, 2012, 5, 94-97.	0.3	0
185	Tumormicroenvironment. Springer Reference Medizin, 2021, , 1-7.	0.0	0
186	Type II HMG-CoA Reductase Inhibitors (Statins) Provide Acute-Graft-Versus-Host Disease Protection by Th-2 Cytokine Induction While Sparing Graft-Versus-Leukemia Activity.. Blood, 2006, 108, 189-189.	0.6	0
187	Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology, 0, 13, .	2.2	0